Intellia Therapeutics: Positive Results from NTLA-2002 in CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia Therapeutics

Intellia Therapeutics (NTLA) is a clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.